Compare Neurocrine Biosciences Inc (NBIX) vs NRG Energy Inc (NRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs NRG Energy Inc — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while NRG Energy Inc trades at $116.91 (market cap $25.15B). The key difference: NRG Energy Inc is the larger of the two by market cap, and NRG Energy Inc pays a 1.59% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | NRG | |
|---|---|---|
Market Cap | $15.77B | $25.15B |
Sector | Health | Utilities |
52-Week High | $185.50 | $184.03 |
52-Week Low | $123.10 | $109.51 |
Enterprise Value | $15.78B | $49.10B |
Dividend Yield | — | 1.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
NRG Energy trades at $119.64, up 0.52% with a bullish technical signal despite recent earnings misses. The stock shows strong profitability metrics including 26.77% ROE and 2.56% net margin, supported by $30.71B revenue in 2025. Recent developments include a transformative 1.2 GW Texas data-center power project and LS Power acquisition, driving long-term growth expectations. Cash flow trends show volatility with 2025 net cash flow of $3.83B followed by projected 2026 outflow of -$264M.
Wall Street maintains strong bullish sentiment with 69% buy ratings and $201.29 consensus target, representing 68% upside. Key risks include rising interest costs impacting earnings, elevated debt levels at 56.42% debt-to-asset ratio, and execution challenges with major capital projects. The data center expansion strategy offers significant growth potential but requires careful monitoring of capex and leverage management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
